CA2290067A1 - Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain - Google Patents

Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain Download PDF

Info

Publication number
CA2290067A1
CA2290067A1 CA002290067A CA2290067A CA2290067A1 CA 2290067 A1 CA2290067 A1 CA 2290067A1 CA 002290067 A CA002290067 A CA 002290067A CA 2290067 A CA2290067 A CA 2290067A CA 2290067 A1 CA2290067 A1 CA 2290067A1
Authority
CA
Canada
Prior art keywords
antibodies
cells
tnf
pathological conditions
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002290067A
Other languages
English (en)
Inventor
Jeremy A. Harrop
Stephen D. Holmes
Manjula P. Reddy
Alemseged Truneh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2290067A1 publication Critical patent/CA2290067A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre de nouveaux membres de la famille des récepteurs du facteur de nécrose des tumeurs (TNF) appelés récepteurs TR2 et leur utilisations dans des états pathologiques. L'invention concerne également des lignées de cellules d'hybridomes produisant de tels anticorps monoclonaux, des méthodes d'imagerie in vivo d'un état pathologique, et des méthodes thérapeutiques et diagnostiques concernant les états pathologiques provoqués par un fonctionnement, une production ou un métabolisme anormal des récepteurs TR2. L'invention concerne enfin des analyses in vitro permettant de détecter la présence de TR2 et d'évaluer l'affinité de liaison d'un composé analysé.
CA002290067A 1997-05-12 1998-05-12 Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain Abandoned CA2290067A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4624997P 1997-05-12 1997-05-12
US60/046,249 1997-05-12
PCT/US1998/009744 WO1998051346A1 (fr) 1997-05-12 1998-05-12 Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain

Publications (1)

Publication Number Publication Date
CA2290067A1 true CA2290067A1 (fr) 1998-11-19

Family

ID=21942431

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290067A Abandoned CA2290067A1 (fr) 1997-05-12 1998-05-12 Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain

Country Status (4)

Country Link
EP (1) EP1009431A4 (fr)
JP (1) JP2001524985A (fr)
CA (1) CA2290067A1 (fr)
WO (1) WO1998051346A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
JP2002540083A (ja) * 1999-03-22 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様２
WO2001079496A2 (fr) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand pour mediateur d'entree du virus herpes simplex et procedes de mise en oeuvre
DE60129010T2 (de) * 2000-04-12 2008-02-28 La Jolla Institute For Allergy And Immunology, San Diego Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
CA2482938A1 (fr) * 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Anticorps se liant specifiquement a tr2
JP2010540660A (ja) * 2007-10-05 2010-12-24 ユニバーシティ オブ メリーランド，ボルチモア 哺乳類内の赤血球生成を刺激する新規の組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO1993023557A1 (fr) * 1992-05-08 1993-11-25 Receptagen Corporation Agents antirecepteurs diriges contre le recepteur de la vitamine b12/transcobalamine ii
WO1994009137A1 (fr) * 1992-10-15 1994-04-28 Genentech, Inc. Anticorps contre le recepteur du facteur de necrose de tumeurs de type 2
EP2017337A1 (fr) * 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Récepteur du facteur onconécrosant humain
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
EP0961832A4 (fr) * 1996-09-18 2003-02-26 Human Genome Sciences Inc Genes de type recepteurs du facteur de necrose tumorale humain

Also Published As

Publication number Publication date
WO1998051346A1 (fr) 1998-11-19
EP1009431A4 (fr) 2000-09-27
EP1009431A1 (fr) 2000-06-21
JP2001524985A (ja) 2001-12-04

Similar Documents

Publication Publication Date Title
EP0521985B1 (fr) Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
EP0705346B1 (fr) Anticorps monoclonaux diriges contre le recepteur du facteur de croissance derive des plaquettes (pdgf) alpha et utilisations de ceux-ci
US10730943B2 (en) Means and methods for treating HBV infection and associated conditions
Ishikawa et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth
Nakada et al. Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment
CA2086325C (fr) Ligand pour le recepteur cd28 sur les cellules b et methodes
EP3271387B1 (fr) Molécules de liaison trispécifiques pour le traitement d'une infection par le vhb et d'états pathologiques associés
US20030026803A1 (en) Compositions for inhibiting macrophage activity
JP2003024083A (ja) モノクローナル抗体５ｃ８が特異的に結合するタンパク質
US20070065875A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
KR20110031222A (ko) 항­ｐ２ｘ７ 펩티드 및 에피토프
JP2004521654A (ja) Ｉｌ−１２及びｉｌ−１８に対する二特異的モノクローナル抗体
EP3856777A1 (fr) Anticorps anti-cd30 et procédés d'utilisation
US6830937B1 (en) Method for generating and identifying antibodies directed against a B7
JP2004526413A (ja) 可溶性ｉｌ−ｔｉｆ／ｉｌ−２２レセプターまたはｉｌ−ｔｉｆ／ｉｌ−２２に結合する結合タンパク質をコードする単離された核酸分子、およびその使用
US20030219446A1 (en) Ligand for CD28 receptor on B cells and methods
Nicola et al. Neutralizing and nonneutralizing monoclonal antibodies to the human granulocyte-macrophage colony-stimulating factor receptor alpha-chain
CA2290067A1 (fr) Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain
CA2466118A1 (fr) Modulation de la fonction des lir dans le traitement de la polyarthrite rhumatoide
WO2023143547A1 (fr) Anticorps anti-cd28 et son utilisation
CN115304680B (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
US20020102258A1 (en) Human tumor necrosis factor receptor-like 2 (TR2) antibodies
US7208152B2 (en) Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
CN113307871B (zh) 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
CA3238260A1 (fr) Compositions de complexes proteiques et leurs procedes d'utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead